Senji Kasahara

Gifu-shi, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 64 publications

Real-world comparison of brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone and anthracycline-based regimens in peripheral T-cell lymphoma: A multicenter retrospective study from the Gifu Hematology Study Group.

Real-world comparison of brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone and anthracycline-based regimens in peripheral T-cell lymphoma: A multicenter retrospective study from the Gifu Hematology Study Group.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: July 30, 2026

A Scalable Feedback-Enabled Cardiopulmonary Resuscitation Training Model and Early Attainment of Guideline-Consistent Compression Skills: A Quasi-Experimental Study.

A Scalable Feedback-Enabled Cardiopulmonary Resuscitation Training Model and Early Attainment of Guideline-Consistent Compression Skills: A Quasi-Experimental Study.

Journal: Prehospital and disaster medicine

Published: July 20, 2026

Transient acquired thrombotic thrombocytopenic purpura developed during bortezomib, lenalidomide, and dexamethasone therapy for multiple myeloma

Transient acquired thrombotic thrombocytopenic purpura developed during bortezomib, lenalidomide, and dexamethasone therapy for multiple myeloma

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: July 08, 2026

Characteristics of Clinical Response in Patients With Chronic Myeloid Leukemia With an ABL1 In-Frame Exon 4 Deletion: A Multicenter Retrospective Study.

Characteristics of Clinical Response in Patients With Chronic Myeloid Leukemia With an ABL1 In-Frame Exon 4 Deletion: A Multicenter Retrospective Study.

Journal: EJHaem

Published: June 27, 2026

Prognostic factors of second allogeneic hematopoietic stem cell transplantation for relapsed or refractory myelodysplastic syndromes: nationwide registry analysis.

Prognostic factors of second allogeneic hematopoietic stem cell transplantation for relapsed or refractory myelodysplastic syndromes: nationwide registry analysis.

Journal: Bone marrow transplantation

Published: May 19, 2026

Pre-transplant molecular international prognostic scoring system score reduction is not associated with improved outcomes in myelodysplastic syndromes.

Pre-transplant molecular international prognostic scoring system score reduction is not associated with improved outcomes in myelodysplastic syndromes.

Journal: Blood cancer journal

Published: March 24, 2026

Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3-ITD-Positive AML.

Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3-ITD-Positive AML.

Journal: Cancer science

Published: March 09, 2026

Severe and/or prolonged COVID-19 in hematologic diseases: clinical implications before and during the omicron era.

Severe and/or prolonged COVID-19 in hematologic diseases: clinical implications before and during the omicron era.

Journal: Frontiers in oncology

Published: August 17, 2025

Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: a real-world study.

Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: a real-world study.

Journal: Annals of hematology

Published: July 13, 2025

NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.

NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.

Journal: Leukemia

Published: June 18, 2025

DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.

DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.

Journal: Leukemia

Published: May 24, 2025

Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High-Dose Cytarabine-Based Chemotherapy as Second-Line Treatments for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High-Dose Cytarabine-Based Chemotherapy as Second-Line Treatments for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Journal: Hematological oncology

Published: May 21, 2025

Showing 1-12 of 64

Last Updated: 09/26/2026